MX2015013699A - Una composicion de galactooligosacaridos para su uso en la prevencion o tratamiento de disfuncion cognitiva y trastornos emociales en enfermedades neuropsiquiatricas o envejecimiento. - Google Patents

Una composicion de galactooligosacaridos para su uso en la prevencion o tratamiento de disfuncion cognitiva y trastornos emociales en enfermedades neuropsiquiatricas o envejecimiento.

Info

Publication number
MX2015013699A
MX2015013699A MX2015013699A MX2015013699A MX2015013699A MX 2015013699 A MX2015013699 A MX 2015013699A MX 2015013699 A MX2015013699 A MX 2015013699A MX 2015013699 A MX2015013699 A MX 2015013699A MX 2015013699 A MX2015013699 A MX 2015013699A
Authority
MX
Mexico
Prior art keywords
ageing
preventing
illnesses
neuropsychiatry
cognitive dysfunction
Prior art date
Application number
MX2015013699A
Other languages
English (en)
Inventor
Georgios Tzortzis
Original Assignee
Clasado Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clasado Inc filed Critical Clasado Inc
Publication of MX2015013699A publication Critical patent/MX2015013699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se describe una composición de galactooligosacáridos que comprende una mezcla de disacáridos, trisacáridos, un tetrasacárido y un pentasacárido para su uso en la prevención o tratamiento de disfunción cognitiva y/o trastornos emocionales en enfermedades neuropsiquiátricas o envejecimiento.
MX2015013699A 2013-03-28 2014-03-17 Una composicion de galactooligosacaridos para su uso en la prevencion o tratamiento de disfuncion cognitiva y trastornos emociales en enfermedades neuropsiquiatricas o envejecimiento. MX2015013699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1305708.8A GB201305708D0 (en) 2013-03-28 2013-03-28 Novel use
PCT/GB2014/050829 WO2014155056A1 (en) 2013-03-28 2014-03-17 A galactooligosaccharide composition for use in preventing or treating cognitive dysfunction and emotional disturbances in neuropsychiatry illnesses or ageing

Publications (1)

Publication Number Publication Date
MX2015013699A true MX2015013699A (es) 2016-05-31

Family

ID=48444941

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013699A MX2015013699A (es) 2013-03-28 2014-03-17 Una composicion de galactooligosacaridos para su uso en la prevencion o tratamiento de disfuncion cognitiva y trastornos emociales en enfermedades neuropsiquiatricas o envejecimiento.

Country Status (19)

Country Link
US (2) US11241449B2 (es)
EP (1) EP2978432B1 (es)
JP (1) JP6309612B2 (es)
KR (2) KR102235730B1 (es)
CN (1) CN105073120A (es)
AR (1) AR095738A1 (es)
AU (1) AU2014242798B2 (es)
BR (1) BR112015024625A2 (es)
CA (1) CA2908230C (es)
ES (1) ES2722852T3 (es)
GB (2) GB201305708D0 (es)
HK (1) HK1204451A1 (es)
IL (1) IL241844B (es)
MX (1) MX2015013699A (es)
MY (1) MY175533A (es)
RU (1) RU2663696C2 (es)
SG (2) SG11201507668UA (es)
TW (1) TWI507198B (es)
WO (1) WO2014155056A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
EP2886140A1 (en) * 2013-12-17 2015-06-24 University of Limerick An apparatus for the extracorporeal treatment of blood
WO2016029113A1 (en) * 2014-08-22 2016-02-25 Abbott Laboratories Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
CN113840611A (zh) * 2019-05-15 2021-12-24 N·V·努特里奇亚 用于治疗肠道屏障功能疾病的β-1,3’-半乳糖基乳糖
CN115089596A (zh) * 2022-06-20 2022-09-23 自然资源部第三海洋研究所 新琼寡糖用于制备治疗抑郁症产品的新用途
GB2623335A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
DE602004006133T3 (de) * 2003-06-30 2014-12-24 Clasado Inc. Neue galactooligosaccharidzusammensetzung und herstellung davon
CN101095698B (zh) * 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
ITMI20071214A1 (it) 2007-06-15 2008-12-16 S I I T Srl Servizio Internazi Composizioni a base di componenti prebiotici ed immunogenici per la prevenzione e il trattamento di disturbi gastroenterici da disbiosi e/o alterazioni della normale flora intestinale
CN101998859B (zh) * 2008-03-18 2014-03-05 亚历山大·弗拉基米罗维奇·季科夫斯基 用于预防与抗生素肠道给药相关的生态失调的药物组合物
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
GB0809921D0 (en) * 2008-05-30 2008-07-09 Clasado Inc Product and process therefor
EP2405918B2 (en) 2009-03-13 2020-09-02 The Regents of The University of California Prebiotic oligosaccharides
MX2012005015A (es) * 2009-10-30 2012-06-12 Prometheus Lab Inc Metodos para diagnosticar sindrome de intestino irritable.
JP6006117B2 (ja) * 2009-11-12 2016-10-12 ネステク ソシエテ アノニム 腸内微生物叢バランス及び健康を促進するための栄養組成物
US20120276208A1 (en) 2011-04-27 2012-11-01 University Of South Australia Acute cognitive and mood effects of plant polysaccharides in adult human subjects

Also Published As

Publication number Publication date
MY175533A (en) 2020-07-01
US11241449B2 (en) 2022-02-08
US20220143054A1 (en) 2022-05-12
KR20150135504A (ko) 2015-12-02
BR112015024625A2 (pt) 2017-07-18
TW201444562A (zh) 2014-12-01
GB201405503D0 (en) 2014-05-14
SG11201507668UA (en) 2015-10-29
GB201305708D0 (en) 2013-05-15
KR102235730B1 (ko) 2021-04-02
CA2908230A1 (en) 2014-10-02
HK1204451A1 (en) 2015-11-20
WO2014155056A1 (en) 2014-10-02
AU2014242798B2 (en) 2018-07-05
TWI507198B (zh) 2015-11-11
KR20210038701A (ko) 2021-04-07
ES2722852T3 (es) 2019-08-19
JP2016516743A (ja) 2016-06-09
EP2978432B1 (en) 2019-02-20
CN105073120A (zh) 2015-11-18
RU2663696C2 (ru) 2018-08-08
AU2014242798A1 (en) 2015-10-08
GB2515865B (en) 2017-05-10
AR095738A1 (es) 2015-11-04
CA2908230C (en) 2021-04-13
US20160045524A1 (en) 2016-02-18
GB2515865A (en) 2015-01-07
EP2978432A1 (en) 2016-02-03
IL241844B (en) 2018-06-28
RU2015146305A (ru) 2017-05-04
SG10201707152TA (en) 2017-10-30
JP6309612B2 (ja) 2018-04-11

Similar Documents

Publication Publication Date Title
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
MX2015013699A (es) Una composicion de galactooligosacaridos para su uso en la prevencion o tratamiento de disfuncion cognitiva y trastornos emociales en enfermedades neuropsiquiatricas o envejecimiento.
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
EP2944323A4 (en) MEANS FOR THE TREATMENT OF TUMORS, USE AND METHOD THEREFOR
IL239921A0 (en) Preparations containing solutions in solid state and their use for the treatment of pain
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
GB201301626D0 (en) Composition comprising 15-OHEPA and methods of using the same
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
EP3015107A4 (en) METHOD FOR TREATING MIBROMED DYNAMIC FUNCTION
IL242437B (en) Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process
PL2988764T3 (pl) Kompozycje przeciwłupieżowe i sposoby ich zastosowania
MY179576A (en) Agent for promoting in vivo absorption of hydroxytyrosol and derivatives thereof and use of same
MX2014015039A (es) Inhibidores de fbx03.
EP2958558A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF LEUKEMIA
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
PL2970696T3 (pl) Dodatek zwiększający efekt tiksotropii i kompozycja zawierająca ten dodatek
EP2894013A4 (en) ISOLATOR, CLEANING BENCH AND CABINET
MX2015016603A (es) Composiciones de corticosteroides.
EP2944370A4 (en) METHOD FOR PRODUCING A COMPOSITION FROM A CONTINUOUS PHASE WITH DISPERSED DISPERSER PHASE AND DEVICE THEREFOR
EP2969579A4 (en) TREATMENT OF AMMONIUM OCTAMOLYBDATE
GB2514225B (en) Systems, apparatuses, and methods for reducing the number of short integer multiplications